Sintilimab plus eribulin and carboplatin in patients with metastatic triple-negative breast cancer (SECURE): a phase II, multicenter trial

Background

The clinical benefit of combining chemotherapy with immunotherapy in metastatic triple-negative breast cancer (TNBC) varies depending on the chemotherapy backbone, highlighting the need for optimizing combination partners. This single-arm exploratory phase II trial evaluated the efficacy and safety of sintilimab combined with eribulin and carboplatin (ErCb) in patients with metastatic TNBC previously treated with anthracyclines and/or taxanes.